Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eisai Ltd ADR (OP:ESALY)

N/A UNCHANGED
Last Price Updated: 3:59 PM EST, Jan 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eisai Ltd ADR

< Previous 1 2 3 4 5 6 7 Next >
Will US Medicare Fully Cover Alzheimer's Drugs? Eli Lilly Thinks Yes!
Eli Lilly And Co (NYSE: LLY) expects the U.S. Medicare health plan to loosen its grip on the coverage limits on new Alzheimer's drugs, as more data emerging in coming weeks show that clearing amyloid... 
Via Benzinga
Merck, Eisai Shelve Keytruda Plus Lenvima Combo Trial In Skin Cancer Setting, Disappoints In Certain Type Of Colorectal Cancer
Via Benzinga
Tesla Manufactured 4,000 Model Ys In One Week, UBS Prepping For Massive Layoffs, McDonald's Temporary Shuttering Of US Offices: Today's Top Stories
Bloomberg UBS Prepping For Massive Layoffs Amid Credit Suisse Takeover 
Via Benzinga
National Institute on Aging Aims Building $300M Alzheimer's Research Database
The U.S. National Institute on Aging (NIA), part of the government's National Institutes of Health (NIH), aims to build an Alzheimer's research database. Alzheimer's Association Chief Science Officer... 
Via Benzinga
Daily Stock Analysis: Eisai
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's activities consist of a pharmaceutical business and other businesses. 
Via Talk Markets
Lecanemab Receives Priority Review Status in Japan
From Eisai
Via JCN Newswire
Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
From Eisai
Via JCN Newswire
FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease
From Eisai
Via JCN Newswire
Eisai-Biogen Highlights Additional Data From Recently Approved Alzheimer's Drug
Via Benzinga
7 Healthcare Stocks to Buy for Long-Term Growth and Stability
These healthcare stocks to buy offer spectacular upside potential ahead in your defensive portfolio as we get deeper into 2023. 
Via InvestorPlace
Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments
Via Benzinga
Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity
Via Benzinga
Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer's Treatment
Via Benzinga
1 Green Flag and 1 Red Flag for Biogen
Biogen beat the bear market this year. 
Via The Motley Fool
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
From Eisai
Via JCN Newswire
Why Anavex Life Sciences Stock Bolted Higher in January
The biotech's shares have been steadily leaking higher following positive late-stage Alzheimer's disease trial results. 
Via The Motley Fool
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga
Is Biogen Stock a No-Brainer Buy After Eli Lilly's Alzheimer's Disease Setback?
Lilly's FDA rejection puts Biogen and its partner Eisai in the driver's seat in the Alzheimer's disease drug market. 
Via The Motley Fool
In A Stunner, Eli Lilly Stock Falls After FDA Delivers A Blow To Its Alzheimer's Drug
The company will need to complete its confirmatory study before asking for approval. 
Via Investor's Business Daily
Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval
The Food and Drug Administration authorized Leqembi under an accelerated approval pathway this month. 
Via The Motley Fool
This Monumental Breakthrough Could Turn the World Upside Down -- and Make Some Investors Filthy Rich
The fountain of youth might not be a myth in the future. 
Via The Motley Fool
Should You Buy Biogen Stock After Its Latest Alzheimer's Disease Drug Approval?
There's more to the story with Biogen after receiving good news for Leqembi. 
Via The Motley Fool
Barron's Top Weekend Stock Picks: Tesla, Snowflake, Delta And Why Warren Buffett's Berkshire Hathaway May Be In For Big Tax Bill
Benzinga reviews this weekend's top stories covered by Barron's, here are the articles investors need to read. 
Via Benzinga
FDA Approves Biogen's Second Alzheimer's Treatment Under Accelerated Pathway
Via Benzinga
Lecanemab Alert: What Would Alzheimer’s Drug Approval Mean for Biogen (BIIB) Stock?
Biogen is in focus today with the company's lecanemab drug set for an FDA decision on approval, leading to bullish bets on BIIB stock. 
Via InvestorPlace
Biogen Could Get A Second Alzheimer's OK — But Will Wild Card Medicare Bite?
CMS already snubbed Biogen's first Alzheimer's drug. Will the second fare better? 
Via Investor's Business Daily
1 Stock Defying the Downturn to Buy, and 1 to Avoid
These two stocks might go in different directions in the future. 
Via The Motley Fool
Top Picks For 2023: Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a small-cap biopharma company focused on in-licensing, developing, and commercializing novel medicines to treat rare diseases. Let's take a closer look to see why it's a top... 
Via Talk Markets
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Biopharma stocks were not immune to the broader market downturn seen for much of 2022. 
Via Benzinga
Biogen's Alzheimer's Antibody Might Have A Third Death Associated With
A third death is supposedly linked with Biogen Inc's (NASDAQ: BIIB) investigational Alzheimer's antibody, lecanemab. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.